Latest News and Press Releases

The U.S. FDA has accepted Chiesi's New Drug Application (NDA) for its investigational maintenance treatment of asthma in adults.

Chiesi and Plug and Play have announced the launch of Breathing Innovation: The Chiesi Challenge for Transformative Respiratory Solutions.

2023 Sustainability Report demonstrates strong impact across Patients, Planet, People and ProsperityUS Community Engagement Strategy will address access to healthcare, food security, environmental...

Presentations will highlight new data in respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD)Data to be presented include new six-month results from a study of a...

Richard Smith brings 25 years of expertise in building commercial excellence and partnering with the healthcare community across multiple therapeutic areasChiesi USA remains steadfast in its...

Chiesi Group announces mid-year turnover of €1,497 millionSubstantial growth of each of Chiesi’s business areasEurope remains the biggest market, followed by the U.S. and ChinaForecasted revenues of...

CARY, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Jon Zwinski, CEO and General Manager at Chiesi USA,...

CARY, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Chiesi USA, Inc. (key-A-zee), a Cary-based specialty pharmaceutical company, in partnership with Smith Anderson, a Triangle-based full-service business...

Turnover at €2 billion 749 million, with growth of 13.6% over 2021The European market remains at the center, with significant international developmentThe distribution of turnover by therapeutic area...

Chiesi’s CSR initiative, Chiesi in the Community, was determined to out-do itself in another year of meaningful community impact.2022 efforts include deepened partnerships with Triangle-area...